Tempest Therapeutics Shares Plunge Following Equity Offering Announcement

Tempest Therapeutics experienced a significant selloff after revealing plans for a substantial capital raise. The clinical-stage biotechnology company saw its stock decline by 12.9% as it moved to offer more than 1.1 million shares priced at $3.625 each. This financing initiative aims to generate approximately $4.25 million to advance the company’s development pipeline.

The scale of this equity offering represents nearly one quarter of Tempest’s current market valuation of $18.52 million. Beyond the common stock issuance, the company also issued unregistered warrants that could potentially yield an additional $4.1 million if fully exercised. Investors responded negatively to the dilutive effect of these transactions, driving the share price below the psychologically significant 10% threshold during pre-market Read more...